Skip to content

Clinical trial related to the effect of different painkillers (etoricoxib and celecoxib). How do these medicaments reduce the pain after the removal of a lower wisdom tooth?

Comparison of the preventive painkiller effect of etoricoxib and celecoxib after M3M surgery: A randomized, double-masked clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2020-001638-37-HU
Enrollment
75
Registered
2020-06-05
Start date
2022-03-28
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

Trade Name: Arcoxia 60 mg filmtabletta Pharmaceutical Form: INN or Proposed INN: etoricoxib CAS Number: 202409-33-4 Other descriptive name: ETORICOXIB Concentration unit: mg milligram(s) Concentratio

Sponsors

Semmelweis Egyetem Fogorvostudományi Kar Arc- Állcsont- Szájsebészeti és Fogászati Klinika, Budapest
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: female and male patients aged between 18 and 30, without any current medical conditions or existing in the medical history. class I and II, A and B positioned (Pell & Gregory) wisdom teeth will be removed (with the exception of Class II B- due to the more invasive surgery a longer healing period is suspected) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 75 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients will be excluded if the following conditions exist: - patients under medication (we would like to avoid the interactions) - patients who have taken any type of a painkiller during the week prior to the surgery - smokers (longer healing period is suspected) - pregnancy - patients in breast feeding period - patients with allergy for the examined medicaments

Design outcomes

Primary

MeasureTime frame
Main Objective: to compare the preventive painkiller efficacy of the examined substances (celecoxib and etoricoxib);Secondary Objective: to evaluate the necessity of the preventive usage of selective COX-2 inhibitors prior to M3M surgery;Primary end point(s): The volume of the postoperative pain will be estimated by the patients on a Visual Analog Scale where 0 means no pain et all ad 10 equals the unbearable pain;Timepoint(s) of evaluation of this end point: pain should be registered in the first 8 hours after the surgery and on the next day of the intervention in three different timepoints (09:00, 15:00 és 21:00)

Secondary

MeasureTime frame
Secondary end point(s): the rate of the discomfort will be registered on a verbal rating scale (VRS-4);Timepoint(s) of evaluation of this end point: the discomfort should be registered in the first 8 hours after the surgery and on the next day of the intervention in three different timepoints (09:00, 15:00 és 21:00)

Countries

Hungary

Contacts

Public ContactSemmelweis Egyetem Fogorvostudomány

Semmelweis Egyetem Fogorvostudományi Kar Arc- Állcsont- Szájsebészeti és Fogászati Klinika Budapest

gyurikomlos@yahoo.com0036304010772

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026